Headed to BIO in San Diego this June? Plan some time to meet with our complex biologics and bioconjugate experts while you’re there.  Our scientific and commercial leadership will be on hand in booth #5019, participating in the in-booth partnering and 1:1 partnering 360.

Whether you’re working through cell line development, optimizing your biologic’s developability, or looking for a fully integrated CDMO partner to de-risk your pipeline, our drug development experts are ready to dig into the science with you.  At Abzena, we believe that true integration matters. From candidate selection through IND-enabling studies, process development, analytical development and GMP manufacturing, our end-to-end capabilities mean your program moves faster — with a single team that knows your molecule at every stage.

Our attending team of drug development experts includes:

• Dr Campbell Bunce, CSO
• Gavin Murdoch, SVP of Commercial Strategy
• Barbara Arnold, Head of North America Business Development
• Jonathan Cruickshank, Head of EU & APAC Business Development
• Kimberly Burrell, SVP of Global Marketing
• John Gill, VP & Scientific Leader- Cell Line Development
• Dr Francisco Velázquez, Sr. Director of Chemistry
• Nana-Yaw Otieku, VP of Business Development
• Evan Wahl, Sr. Director, Business Management
• Kevin Ranke, Sr. Director of Business Development
• Parth Shah, Director of R&D Business Development

Let’s talk about what’s standing between your program and its next milestone. Schedule some time to speak with our team at BIO:

We will also be hosting a panel discussion in the Bioprocessing Theater on the exhibition floor in booth #5725 on Wednesday, June 24th, from 11 am to 12 pm.

Panel Talk Title – Integrated CLD: Manufacturability to GMP-Ready by Design

We’re entering an exciting new era of drug development, defined by increasingly sophisticated biologics, including bispecific antibodies and fusion proteins, as well as rapidly emerging bioconjugate modalities, such as antibody-oligonucleotide conjugates (AOCs). These next-generation therapeutics are expanding what’s possible for patients, enabling more precise targeting, novel mechanisms of action, and access to disease biology that has historically been difficult to address.

Across these modalities, Abzena’s experience points to a consistent theme: scientific promise alone is not enough to create a successful medicine. As molecular formats become more complex, developability and manufacturability must be considered from the earliest stages of discovery and development. Candidates need to demonstrate not only compelling biology but also the stability, productivity, product quality, analytical profile, and process robustness required to progress efficiently through development and into reliable clinical and commercial supply.

A robust and capable cell line development platform is therefore a critical enabler of the next generation of biologics. Such platforms, like AbZelectPRO™, support diverse and challenging molecular architectures, deliver high-producing and genetically stable cell lines, and provide a strong foundation for scalable manufacturing. By integrating cell line engineering, developability assessment, and manufacturability insight, drug developers can increase the probability of technical success, accelerate timelines, and ensure that innovative biologics can ultimately be manufactured at the quality and scale required for patients.

In this panel discussion, experts from Abzena &Syner-G BioPharma Group will discuss how an integrated approach to cell line development and developability can help drug developers navigate this new era of biologics with greater confidence and speed.

Panelists Include

• Campbell Bunce, PhD – CSO at Abzena
• Scott Rudge, PhD – Founder & Principal Consultant at Syner-G Biopharma
• John Gill – VP & Scientific Leader of Cell Line Development